NEOPLASMS
Clinical trials for NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NEOPLASMS trials appear
Sign up with your email to follow new studies for NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New targeted pill takes on chemo for rare lung cancer
Disease control TerminatedThis study tested a new targeted drug, pralsetinib, against standard chemotherapy in people with a specific type of advanced lung cancer (RET fusion-positive) who had not yet received treatment for their metastatic disease. The goal was to see if pralsetinib could better delay ca…
Matched conditions: NEOPLASMS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 01, 2026 15:29 UTC
-
Cancer drug combo tested in kids, but study stopped early
Disease control TerminatedThis early-phase study aimed to find a safe dose of two drugs (niraparib and dostarlimab) given together to children and teens (ages 6 months to 18 years) with solid tumors that had come back or not responded to treatment. The goal was to see if the combination could shrink tumor…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New cancer drug combo shows early promise in small trial
Disease control TerminatedThis early-phase study tested a new drug (PF-07826390) alone or with another drug (sasanlimab) in 10 people with advanced solid tumors like lung, colon, or kidney cancer. The main goals were to check safety and find the right dose. The study was stopped early, so results are limi…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
Kidney cancer drug combo trial halted early
Disease control TerminatedThis study tested a new drug (NKT2152) combined with two other medicines (palbociclib and sasanlimab) in people with advanced clear cell kidney cancer that had gotten worse after prior treatments. The goal was to see if the combination was safe and could shrink tumors. The trial …
Matched conditions: NEOPLASMS
Phase: PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC